ArticleJournal of biomedical optics2017
Performance assessment of diffuse optical spectroscopic imaging instruments in a 2-year multicenter breast cancer trial
Article in Journal of biomedical optics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Impact of clinical factors on the diagnostic performance of diffuse optical spectroscopic imaging for breast cancer.Scientific reports · 2025Article
- Review of recent advances in frequency-domain near-infrared spectroscopy technologies [Invited].Biomedical optics express · 2023Review
- Stable tissue-mimicking phantoms for longitudinal multimodality imaging studies that incorporate optical, CT, and MRI contrast.Journal of biomedical optics · 2023Article
- Water and lipid content of breast tissue measured by six-wavelength time-domain diffuse optical spectroscopy.Journal of biomedical optics · 2022Article
- Diffuse optical spectroscopic method for tissue and body composition assessment.Journal of biomedical optics · 2022Article
- A scalable, multi-wavelength, broad bandwidth frequency-domain near-infrared spectroscopy platform for real-time quantitative tissue optical imaging.Biomedical optics express · 2021Article
- Performance Assessment of a Commercial Continuous-Wave Near-Infrared Spectroscopy Tissue Oximeter for Suitability for Use in an International, Multi-Center Clinical Trial.Sensors (Basel, Switzerland) · 2021Article
- Evaluation of Hemodynamics in a Murine Hindlimb Ischemia Model Using Spatial Frequency Domain Imaging.Lasers in surgery and medicine · 2021Article
- Breast cancer differential diagnosis using diffuse optical spectroscopic imaging and regression with z-score normalized data.Journal of biomedical optics · 2021Article
- Quantitative diffuse optical spectroscopy for noninvasive measurements of the malaria pigment hemozoin.Biomedical optics express · 2020Article
- Tissue oxygen saturation predicts response to breast cancer neoadjuvant chemotherapy within 10 days of treatment.Journal of biomedical optics · 2018Article
- Frequency domain diffuse optical spectroscopy with a near-infrared tunable vertical cavity surface emitting laser.Optics express · 2018Article
- Impact of errors in experimental parameters on reconstructed breast images using diffuse optical tomography.Biomedical optics express · 2018Article
- Vertical-cavity surface-emitting laser sources for gigahertz-bandwidth, multiwavelength frequency-domain photon migration.Journal of biomedical optics · 2017Article
- Optical Breast Imaging: A Review of Physical Principles, Technologies, and Clinical Applications.Journal of breast imagingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
We present a framework for characterizing the performance of an experimental imaging technology, diffuse optical spectroscopic imaging (DOSI), in a 2-year multicenter American College of Radiology Imaging Network (ACRIN) breast cancer study (ACRIN-6691). DOSI instruments combine broadband frequency-domain photon migration with time-independent near-infrared (650 to 1000 nm) spectroscopy to measure tissue absorption and reduced scattering spectra and tissue hemoglobin, water, and lipid composition. The goal of ACRIN-6691 was to test the effectiveness of optically derived imaging endpoints in predicting the final pathologic response of neoadjuvant chemotherapy (NAC). Sixty patients were enrolled over a 2-year period at participating sites and received multiple DOSI scans prior to and during 3- to 6-month NAC. The impact of three sources of error on accuracy and precision, including different operators, instruments, and calibration standards, was evaluated using a broadband reflectance standard and two different solid tissue-simulating optical phantoms. Instruments showed <0.0010 mm−1 (10.3%) and 0.06 mm−1 (4.7%) deviation in broadband absorption and reduced scattering, respectively, over the 2-year duration of ACRIN-6691. These variations establish a useful performance criterion for assessing instrument stability. The proposed procedures and tests are not limited to DOSI; rather, they are intended to provide methods to characterize performance of any instrument used in translational optical imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.